Long-Acting Opioids May Increase Risk of All-Cause Mortality

This article originally appeared here.
Share this content:
Long-Acting Opioids May Increase Risk of All-Cause Mortality
Long-Acting Opioids May Increase Risk of All-Cause Mortality

TUESDAY, June 14, 2016 (HealthDay News) -- Opioid use may significantly increase mortality risk, according to a study published in the June 14 issue of the Journal of the American Medical Association.

Wayne Ray, Ph.D., from the department of health policy at the Vanderbilt University School of Medicine in Nashville, Tenn., and colleagues analyzed data collected between 1999 and 2012 on 22,912 patients, average age 48, who had been prescribed a long-acting opioid medication. The researchers compared that to data on an equal number of patients who had been given an alternate pain medication, including anticonvulsants and low-dose antidepressants.

During an average tracking period of about four to six months, there were 185 deaths in the opioid group versus 87 deaths in the alternate medication group. In all, the opioid group was found to face a 64 percent increased risk of death due to any reason, the team found. But the opioid patients also faced a 65 percent increased risk of death specifically related to new cardiovascular complications.

The study authors concluded that alternate pain medications should be favored over long-acting opioids whenever possible, particularly for those patients who have a history of cardiovascular disease, heart attack, or diabetes. "Our opinion, which is consistent with the recent guidelines from the U.S. Centers for Disease Control and Prevention, is that opioids should be used as a last resort," Ray told HealthDay. "The best way to decide if the benefits outweigh the risks is through a careful practitioner-patient discussion."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »